ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Editas Medicine Inc

Editas Medicine Inc (EDIT)

2,71
-0,28
(-9,36%)
Geschlossen 07 Juni 10:00PM
2,7313
0,0213
(0,79%)
Nach Börsenschluss: 1:54AM

Editas Medicine Inc (EDIT) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
2,7313
( -8,65% )
Gebot
2,31
Fragen
3,43
Volumen
2.366.272
2,63 Tagesbereich 3,00
1,66 52-Wochen-Bereich 4,5372
Marktkapitalisierung
Handelsende
2,99
Handelsbeginn
2,94
Letzte Trade
16
@
2.76
Letzter Handelszeitpunkt
Finanzvolumen
US$ 6.479.774
VWAP
2,7384
Durchschnittliches Volumen (3 Mio.)
US$ 1.994.967
Ausgegebene Aktien
153.461.838
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-2,94
Gewinn pro Aktie (EPS)
-1,18
Erlöse (LTM)
38,69M
Nettogewinn (LTM)
-108,95M

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed ... Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
Cambridge, United States
Gegründet
2026
Editas Medicine Inc is listed in the Healthcare sector of the NASDAQ with ticker EDIT. The last closing price for Editas Medicine was US$2,99. Over the last year, Editas Medicine shares have traded in a share price range of US$ 1,66 to US$ 4,5372.

Editas Medicine currently has 153.461.838 shares in issue. The market capitalisation of Editas Medicine is US$419,15 million. Editas Medicine has a price to earnings ratio (PE ratio) of -2.94.

EDIT Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.6787-19.90322580653.413.512.6333267853.08541775CS
4-0.2987-9.858085808583.033.942.4131746493.18384925CS
120.15135.864341085272.583.942.1320061903.01842475CS
260.271311.02845528462.463.941.6619213492.58207109CS
520.931351.73888888891.84.53721.6622004392.76695986CS
156-6.9387-71.75491209939.6711.910.910121870514.26795472CS
260-31.2487-91.962036492133.9873.0250.9101201443010.55454562CS

EDIT - Frequently Asked Questions (FAQ)

What is the current Editas Medicine Inc share price?
The current share price of Editas Medicine Inc is US$ 2,7313
How many Editas Medicine Inc shares are in issue?
Editas Medicine Inc has 153.461.838 shares in issue
What is the market cap of Editas Medicine Inc?
The market capitalisation of Editas Medicine Inc is USD 419,15M
What is the 1 year trading range for Editas Medicine Inc share price?
Editas Medicine Inc has traded in the range of US$ 1,66 to US$ 4,5372 during the past year
What is the PE ratio of Editas Medicine Inc?
The price to earnings ratio of Editas Medicine Inc is -2,94
What is the cash to sales ratio of Editas Medicine Inc?
The cash to sales ratio of Editas Medicine Inc is 13,72
What is the registered address of Editas Medicine Inc?
The registered address for Editas Medicine Inc is 11 Hurley Street, Cambridge, Massachusetts, 02141
What is the Editas Medicine Inc website address?
The website address for Editas Medicine Inc is www.editasmedicine.com
Which industry sector does Editas Medicine Inc operate in?
Editas Medicine Inc operates in the Biotechnology & Life Sciences sector

EDIT Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen